Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBITDA (2023 - 2025)

Contineum Therapeutics has reported EBITDA over the past 3 years, most recently at -$15.2 million for Q4 2025.

  • Quarterly results put EBITDA at -$15.2 million for Q4 2025, down 0.7% from a year ago — trailing twelve months through Dec 2025 was -$59.8 million (down 41.36% YoY), and the annual figure for FY2025 was -$59.8 million, down 41.36%.
  • EBITDA for Q4 2025 was -$15.2 million at Contineum Therapeutics, down from -$12.7 million in the prior quarter.
  • Over the last five years, EBITDA for CTNM hit a ceiling of $41.5 million in Q2 2023 and a floor of -$16.1 million in Q2 2025.
  • Median EBITDA over the past 3 years was -$9.3 million (2024), compared with a mean of -$6.6 million.
  • Biggest five-year swings in EBITDA: crashed 121.87% in 2024 and later dropped 0.7% in 2025.
  • Contineum Therapeutics' EBITDA stood at -$7.6 million in 2023, then tumbled by 98.82% to -$15.1 million in 2024, then decreased by 0.7% to -$15.2 million in 2025.
  • The last three reported values for EBITDA were -$15.2 million (Q4 2025), -$12.7 million (Q3 2025), and -$16.1 million (Q2 2025) per Business Quant data.